Figure S2 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Wei Xiao,Mohammed L. Ibrahim,Priscilla S. Redd,John D. Klement,Chunwan Lu,Dafeng Yang,Natasha M. Savage,Kebin Liu

DOI: https://doi.org/10.1158/1541-7786.22516104.v1

2023-01-01

Abstract:Loss of Fas function leads to resistance to FasL-induced apoptosis.

What problem does this paper attempt to address?

Clinical Value of FAT1 Mutations to Indicate the Immune Response in Colorectal Cancer Patients.

Wei Zhu,Lan Yang,Yu Gao,Yi Zhou,Yuqian Shi,Kaihua Liu,Ruoying Yu,Yang Shao,Wentong Zhang,Guosheng Wu,Junjun He

DOI: https://doi.org/10.1016/j.ygeno.2024.110808

IF: 4.31

2024-01-01

Genomics

Abstract:Immunotherapy is currently approved for CRC whose tumors have high MSI-H. To find additional biomarkers for immunotherapy in CRC, targeted sequencing was performed on tumor tissues from a discovery cohort of 161 CRC patients. Validation cohorts from the cBioPortal were also used for survival and tumor cell infiltration analyses. The FAT1-mutated CRC group often co-occurred with MSI events and displayed a higher tumor mutational burden compared to the FAT1 wild-type CRC. Overall survival was higher in patients with FAT1 mutations than in patients with wild type FAT1. The altered PI3K-AKT pathway and immune pathways were enriched in the FAT1-mutated CRC. A higher infiltration rate of immune cells including CD4+ T cells, CD8+ T cells, macrophages M1 and regulatory T cells were also observed in the colorectal tumors with FAT1 mutation compared to tumors with wild type FAT1. The results showed that CRC patients with FAT1 mutations exhibited an immunotherapy-favorable profile.
Blockade of Fas Signaling in Breast Cancer Cells Suppresses Tumor Growth and Metastasis Via Disruption of Fas Signaling-initiated Cancer-related Inflammation*

Qiuyan Liu,Qinchun Tan,Yuanyuan Zheng,Kun Chen,Cheng Qian,Nan Li,Qingqing Wang,Xuetao Cao

DOI: https://doi.org/10.1074/jbc.m113.525014

IF: 5.485

2014-01-01

Journal of Biological Chemistry

Abstract:Mechanisms for cancer-related inflammation remain to be fully elucidated. Non-apoptotic functions of Fas signaling have been proposed to play an important role in promoting tumor progression. It has yet to be determined if targeting Fas signaling can control tumor progression through suppression of cancer-related inflammation. In the current study we found that breast cancer cells with constitutive Fas expression were resistant to apoptosis induction by agonistic anti-Fas antibody (Jo2) ligation or Fas ligand cross-linking. Higher expression of Fas in human breast cancer tissue has been significantly correlated with poorer prognosis in breast cancer patients. To determine whether blockade of Fas signaling in breast cancer could suppress tumor progression, we prepared an orthotopic xenograft mouse model with mammary cancer cells 4T1 and found that blockade of Fas signaling in 4T1 cancer cells markedly reduced tumor growth, inhibited tumor metastasis in vivo, and prolonged survival of tumor-bearing mice. Mechanistically, blockade of Fas signaling in cancer cells significantly decreased systemic or local recruitment of myeloid derived suppressor cells (MDSCs) in vivo. Furthermore, blockade of Fas signaling markedly reduced IL-6, prostaglandin E2 production from breast cancer cells by impairing p-p38, and activity of the NFκB pathway. In addition, administration of a COX-2 inhibitor and anti-IL-6 antibody significantly reduced MDSC accumulation in vivo. Therefore, blockade of Fas signaling can suppress breast cancer progression by inhibiting proinflammatory cytokine production and MDSC accumulation, indicating that Fas signaling-initiated cancer-related inflammation in breast cancer cells may be a potential target for treatment of breast cancer.
Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

Wei Zhang,Er-Xun Ding,Qiang Wang,Da-Qiao Zhu,Jin He,Li,Yuan-He Wang

DOI: https://doi.org/10.3748/wjg.v11.i23.3632

IF: 5.374

2005-01-01

World Journal of Gastroenterology

Abstract:AIM:To detect the expression of Fas ligand (FasL) in colon cancer tissues and cell lines and analyze the function of FasL-expressing colon cancer cells in inducing Fas-sensitive T lymphocyte apoptosis.METHODS:Ninety surgically resected colon cancer tissues and 15 hepatic metastasis specimens were investigated by immunohistochemical method with normal colon mucosa and colon adenoma as control. The relationship between FasL expression and pathologic features was also analyzed. FasL expression of 4 colon cancer cell lines, SW620, Lovo, LS-174T and SW1116, were detected by Western blotting assay. The function of FasL expressed on colon cancer cells was determined by coculture assay with Jurkat T lymphocytes, the apoptotic rate of which was detected by flow cytometry assay.RESULTS:Fifty-six (62.22%) cases of all the 90 colon cancer tissues and all (100%) the liver metastasis specimens expressed FasL, significantly higher than normal colon mucosa and colonic adenoma. Higher expression of FasL was found in more advanced stage of colon cancer and in cancer tissues with lymphatic or hepatic metastasis. All the colon cancer cell lines were found to express FasL. After coculture with the SW1116 cells for 24 h with an effector: target ratio 10:1, the rate of apoptosis of Jurkat cells rose from 1.9% to 21.0%.CONCLUSION:The expression of FasL is upregulated in colon cancer and the functionally expressed FasL can induce apoptosis of Fas-expressing T lymphocytes.
FOS+ B Cells: Key Mediators of Immunotherapy Resistance in Diverse Cancer Types

Xiangyang Zhang,Jiayao Ma,Yihong Chen,Xiangying Deng,Yan Zhang,Ying Han,Jun Tan,Gongping Deng,Yanhong Ouyang,Yulai Zhou,Changjing Cai,Shan Zeng,Hong Shen

DOI: https://doi.org/10.1016/j.omton.2024.200895

2024-01-01

Abstract:While immunotherapy has marked significant advances in cancer treatment, resistance remains a challenge. The complexity of the tumor microenvironment, particularly the role of B cell subpopulations, is a critical factor affecting treatment efficacy. In this study, we conducted analyses of single-cell RNA sequencing data from immunotherapy patients (n = 25) to explore the biomarker of immunotherapy resistance. Spatial transcriptome analysis, immunofluorescence analysis, and multi-cancer immunotherapy transcriptome analysis (n = 1,253) were used to validate our finding, and the potential mechanisms were explored. FOS+ B cells, identified across multiple cancer types, were associated with poor response to immunotherapy. FOS may form AP-1 (activator protein 1) with JUNB, thereby promoting the expression of Blimp-1 and subsequently facilitating the differentiation of B cells into immunosuppressive plasma cells. Furthermore, FOS+ B cells were linked to altered tumor necrosis factor signaling pathways, suggesting a mechanism for their immunosuppressive effects. Our findings highlight FOS+ B cells as important players in immunotherapy resistance, providing a novel biomarker for predicting treatment response. This study not only deepens our understanding of the immunological landscape influencing immunotherapy efficacy but also opens avenues for targeted interventions to overcome resistance.
Loss of Fas Expression and High Expression of HLA-E Promoting the Immune Escape of Early Colorectal Cancer Cells.

Renxiang Huang,Dongyang Zhang,Feng Li,Zili Xiao,Meilin Wu,Dongyun Shi,Ping Xiang,Zhijun Bao

DOI: https://doi.org/10.3892/ol.2017.5891

2017-01-01

Oncology Letters

Abstract:Previous studies have investigated the mechanisms of immune evasion of tumor cells in numerous types of advanced solid malignant tumor, and several types of immune preparations have been administered as antitumor adjuvant therapies. However, in the majority of studies, the efficacy of therapies has been revealed to be limited. The present study aimed to investigate the immune evasion mechanisms employed by early colorectal cancer cells and the expression of the molecules associated with immune evasion during the malignant transformation process of normal colorectal epithelial cells to measure the effects of immune intervention for early colorectal cancer, and to improve the efficacy of immunotherapy. A total of 60 colorectal tissues, including 15 normal mucosa, 15 adenoma, 15 early cancer and 15 advanced cancer tissues, from patients undergoing endoscopic procedures in Huadong Hospital Affiliated to Fudan University (Shanghai, China) were collected. A comparison of baseline characteristics among these four groups was performed. The expression levels of human leukocyte antigen-A (HLA-A), apoptosis antigen 1 (Fas), c-c chemokine receptor type 5 (CCR5), Fas ligand (FasL) and HLA-E in each group were detected by immunohistochemical analysis. Furthermore, 15 patients with advanced colorectal cancer were enrolled into the present study. Advanced cancer and paracancer tissues (normal mucosal tissues 3 cm away from the margin of cancer tissues) were collected from each patient by colonoscopic biopsy. The expression levels of HLA-A, Fas, CCR5, FasL and HLA-E in each group were detected by western blot analysis. During the malignant transformation process of normal colorectal epithelial cells, the expression levels of CCR5, FasL and HLA-E increased significantly (P<0.001), whilst the expression levels of Fas reduced significantly (P=0.0271). In the early cancer group, the expression levels of Fas reduced significantly (P=0.0239), whilst the expression levels of HLA-E increased significantly (P<0.001) compared with adenoma group. In conclusion, a loss of Fas expression and high expression levels of HLA-E may promote the immune evasion of early colorectal cancer cells.
Fas-mediated Pathway and Apoptosis in Normal Cervix, Cervical Intraepithelial Neoplasia and Cervical Squamous Cancer.

Jian-Hong Zhou,Huai-Zeng Chen,Feng Ye,Wei-Guo Lu,Xing Xie

DOI: https://doi.org/10.3892/or.16.2.307

2006-01-01

Oncology Reports

Abstract:The aim of this study was to examine the expression patterns of apoptosis-related antigens, such as Fas, FasL, and cFLIP, in cervical squamous cells, and investigate the role of Fas-mediated apoptosis in the pathogenesis of cervical neoplasia. Using specific antibodies for Fas, FasL, and cFLIP, we examined protein expression in 19 specimens of normal cervix, 15 mild dysplasia (CIN I), 22 moderate dysplasia (CIN II), 23 severe dysplasia (CIN III), and 34 invasive squamous cell carcinoma (SCC) by immunohistochemistry. We detected the apoptotic indices by TUNEL in the same specimens. Fas expression levels were quite similar in CIN I, CIN II and the normal cervix. Though Fas expression tended to increase in grade 2 cancer compared to grade 1 cancer and CIN III, and a slight decline was present in grade 3 compared with grade 2 cancer, these differences did not reach statistical significance. Almost all CINs did not express FasL, while FasL expression increased with the grade of the tumor. Statistically significant differences could be observed between grade 1 and grade 2 (p<0.01) and between grade 2 plus grade 3 and grade 1 (p<0.001). All cases of normal cervix and CIN, except two cases of CIN III, did not express cFLIP. cFLIP expression tended to increase with the grade of the tumor. Apoptosis was determined in all samples by TUNEL. There was a decreasing tendency of apoptotic cells from normal cervix to cancers. A negative correlation between cFLIP and apoptosis (r=-0.499 and p=0.000) was observed. Deregulated Fas/FasL system and constitutive expression of cFLIP in SCC may be an important mechanism by which SCCs escape apoptosis during the malignant transformation and progression of these tumors.
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

P R Walker,P Saas,P Y Dietrich

DOI: https://doi.org/10.4049/jimmunol.158.10.4521

1997-05-15

The Journal of Immunology

Abstract:Abstract Several different tumor types have recently been shown to express functional Fas ligand (FasL), which may represent an additional mechanism of tumor escape. However, the in vivo significance of these findings in the context of potent adversaries such as activated CTL or NK cells remains to be fully established. The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies.

immunology
Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

Fei Yang,Yinxiang Wei,Zhijian Cai,Lei Yu,Lingling Jiang,Chengyan Zhang,Huanmiao Yan,Qingqing Wang,Xuetao Cao,Tingbo Liang,Jianli Wang

DOI: https://doi.org/10.1038/cmi.2014.21

2014-01-01

Abstract:The Fas/FasL system transmits intracellular apoptotic signaling, inducing cell apoptosis. However, Fas signaling also exerts non-apoptotic functions in addition to inducing tumor cell apoptosis. For example, Fas signaling induces lung cancer tumor cells to produce prostaglandin E2 (PGE2) and recruit myeloid-derived suppressor cells (MDSCs). Activated cytotoxic T lymphocytes (CTLs) induce and express high levels of FasL, but the effects of Fas activation initiated by FasL in CTLs on apoptosis-resistant tumor cells remain largely unclear. We purified activated CD8(+) T cells from OT-1 mice, evaluated the regulatory effects of Fas activation on tumor cell escape and investigated the relevant mechanisms. We found that CTLs induced tumor cells to secrete PGE2 and increase tumor cell-mediated chemoattraction of MDSCs via Fas signaling, which was favorable to tumor growth. Our results indicate that CTLs may participate in the tumor immune evasion process. To the best of our knowledge, this is a novel mechanism by which CTLs play a role in tumor escape. Our findings implicate a strategy to enhance the antitumor immune response via reduction of negative immune responses to tumors promoted by CTLs through Fas signaling.
Suppression of Tumor Cell Immune Counterattack by Blocking FasL Expression in Pancreatic Cancer Cells

徐伟,徐高四,虞春华,刘巧云,方义湖

DOI: https://doi.org/10.3969/j.issn.1673-5269.2008.18.008

2008-01-01

Abstract:OBJECTIVE: To investigate if the supression of FasL expression in pancreatic cancer cells can inhibite tumor cell immune in vivo.METHODS: A cDNA fragment complementary,when transcribed,from nucleotides 35 to 371 of the mouse FasL mRNA sequence was amplified by PCR.The fragment was cloned into the StuI site of pBlast expression vector.Panc-1 cells were transfected with plasmid DNA.The suppression of FasL expression in stably transfected clones was determined by Western blot for FasL protein.Soluble FasL was detected in the culture supernatant of Panc-1 cells by ELISA.C57BL/6 mice were injected with tumor cells suspended.Tumor growth was monitored by measuring the width and length of the tumors.The level of lymphocyte infiltration in the excised tumors was assessed.RESULTS: FasL expression in hepatic cancer cells was down-regulated following stable transfection with a plasmid encoding antisense FasL cDNA,and with 80% decrease of FasL expression in plasmidtrans-trans pected cells.Down-regulation of FasL expression on pancreatic cancer cells had no effect on tumor growth in vitro,but significantly reduced tumor development in syngeneic immunocompetent mice in vivo.Mean tumor diameters was 1.53 mm in the group transfected with plasmid DNA,versus 2.98 mm in the group not transfected with plasmid DNA,and the difference was significant between the two groups,P0.01.Compared with the group not transfected with plasmid DNA,the absolute number of CD45+ TIL was increased by 3.23 times in the group transfected with plasmid DNA,P0.01.CONCLUSION: Down-regulation of FasL expression by pancreatic cancer cells results in an improved anti-tumor immune challenge in vivo,providing experimental evidence for counterattack as a mechanism of tumor immune evasion.
FasL Expression in Human Colon Carcinomas

Xing Bao-cai,Wang Yi,S Wimmenauer,E H Farthmann,Huang Xin-fu

DOI: https://doi.org/10.1007/s11670-002-0008-5

2002-01-01

Abstract:Objective: The Fas and Fas ligand (FasL) play an important role in maintaining immune privilege on malignant tumors. In present study, we investigated the expression of FasL in SW480 and LS174 human colon carcinoma cell lines and twenty primary colon carcinoma specimens. Methods: The expression of FasL in human colon carcinoma cell lines and primary colon carcinomas specimens was detected by immunohistochemistry and Reverse Transcription-PCR (RT-PCR). Results: We found that all of detected human colon carcinoma cell lines and primary colon carcinoma specimens constitutively expressed FasL at the mRNA and protein level. However, the expression of FasL was not found in normal colon epithelial cells. Conclusion: The expression of FasL may occur during malignant transformation from normal colon epithelial cells to colon carcinoma cells. Our results suggest that tumor cells kill cytotoxic T lymphocytes (CTLS) and natural killer (NK) cells by expression of FasL. It may be a new mechanism for tumor cells to escape the host’s immune surveillance. The expression of FasL may contribute to the formation of colon carcinomas.
Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status

Julie M Michael-Robinson,Nirmala Pandeya,Margaret C Cummings,Michael D Walsh,Joanne P Young,Barbara A Leggett,David M Purdie,Jeremy R Jass,Graham L Radford-Smith

DOI: https://doi.org/10.1002/path.1406

Abstract:Expression of membrane-bound Fas ligand (FasL) by colorectal cancer cells may allow the development of an immune-privileged site by eliminating incoming tumour-infiltrating lymphocytes (TILs) in a Fas-mediated counter-attack. Sporadic colorectal cancer can be subdivided into three groups based on the level of DNA microsatellite instability (MSI). High-level MSI (MSI-High) is characterized by the presence of TILs and a favourable prognosis, while microsatellite-stable (MSS) cancers are TIL-deficient and low-level MSI (MSI-Low) is associated with an intermediate TIL density. The purpose of this study was to establish the relationship between MSI status and FasL expression in primary colorectal adenocarcinoma. Using immunohistochemistry and a selected series of 101 cancers previously classified as 31 MSI-High, 30 MSI-Low, and 40 MSS, the present study sought to confirm the hypothesis that increased TIL density in MSI-High cancers is associated with low or absent membrane-bound FasL expression, while increased FasL in MSS cancers allows the killing of host TILs. TUNEL/CD3 double staining was also used to determine whether MSS cancers contain higher numbers of apoptotic TILs in vivo than MSI-High or MSI-Low cancers. Contrary to the initial hypothesis, it was found that MSI-High cancers were associated with higher FasL expression (p = 0.04) and a stronger intensity of FasL staining (p = 0.007). In addition, mucinous carcinomas were independently characterized by increased FasL expression (p = 0.03) and staining intensity (p = 0.0005). Higher FasL expression and staining intensity did not correlate with reduced TIL density or increased numbers of apoptotic TILs. However, consistent with the hypothesis that curtailment of the host anti-tumour immune response contributes to the poor prognosis in MSS cancers, it was found that apoptotic TILs were most abundant in MSS carcinomas and metastatic Dukes' stage C or D tumours (p = 0.004; p = 0.046 respectively). This study therefore suggests that MSS colorectal cancers are killing incoming TILs in an effective tumour counter-attack, but apparently not via membrane-bound FasL.
Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In Vivo

Zeinab Y Al Subeh,Dakota B Poschel,Priscilla S Redd,John D Klement,Alyssa D Merting,Dafeng Yang,Megh Mehta,Huidong Shi,Yolonda L Colson,Nicholas H Oberlies,Cedric J Pearce,Aaron H Colby,Mark W Grinstaff,Kebin Liu

DOI: https://doi.org/10.1021/acsnano.2c04420

IF: 17.1

2022-08-23

ACS Nano

Abstract:Fas ligand (FasL), expressed on the surface of activated cytotoxic T lymphocytes (CTLs), is the physiological ligand for the cell surface death receptor, Fas. The Fas-FasL engagement initiates diverse signaling pathways, including the extrinsic cell death signaling pathway, which is one of the effector mechanisms that CTLs use to kill tumor cells. Emerging clinical and experimental data indicate that Fas is essential for the efficacy of CAR-T cell immunotherapy. Furthermore, loss of Fas expression is a hallmark of human melanoma. We hypothesize that restoring Fas expression in tumor cells reverses human melanoma resistance to T cell cytotoxicity. DNA hypermethylation, at the FAS promoter, down-regulates FAS expression and confers melanoma cell resistance to FasL-induced cell death. Forced expression of Fas in tumor cells overcomes melanoma resistance to FasL-induced cell death in vitro. Lipid nanoparticle-encapsulated mouse Fas-encoding plasmid therapy eliminates Fas+ tumor cells and suppresses established melanoma growth in immune-competent syngeneic mice. Similarly, lipid nanoparticle-encapsulated human FAS-encoding plasmid (hCOFAS01) therapy significantly increases Fas protein levels on tumor cells of human melanoma patient-derived xenograft (PDX) and suppresses the established human melanoma PDX growth in humanized NSG mice. In human melanoma patients, FasL is expressed in activated and exhausted T cells, Fas mRNA level positively correlates with melanoma patient survival, and nivolumab immunotherapy increases FAS expression in tumor cells. Our data demonstrate that hCOFAS01 is an effective immunotherapeutic agent for human melanoma therapy with dual efficacy in increasing tumor cell FAS expression and in enhancing CTL tumor infiltration.
Fes-deficient macrophages enhance CD8+ T cell priming and tumour control through increased proinflammatory cytokine production and presentation

Brian J Laight,Danielle Harper,Natasha Dmytryk,Connie S Zhang,Andrew Garven,Changnian Shi,Richard Nauman,Jacob Kment,Faizah Alotaibi,Yan Gao,Caitlyn Vlasschaert,David LeBrun,Kathrin Tyryshkin,David M Berman,Amber L Simpson,Charles Graham,Andrew Craig,Sameh Basta,Madhuri Koti,Peter A Greer

DOI: https://doi.org/10.1101/2024.02.27.581601

2024-06-01

Abstract:Activating the immune system is crucial for successful cancer immunotherapies, various proteins, such as the Fes non-receptor tyrosine kinase exist to limit activation and maintain homeostasis. However, in cancer settings, this serves as a barrier to the desired effects of immune activation following immunomodulatory treatment. Here, we demonstrate the role of Fes, a protein abundantly expressed in macrophages, as a novel innate intracellular immune checkpoint. Fes inactivity is associated with delayed tumour onset in a dose-dependent manner, and its deletion delays tumour growth, improves survival, enhances response to doxorubicin treatment, and sensitizes resistant tumours to PD-1 immune checkpoint inhibition. These effects are associated with an increase in Toll-like receptor signaling in antigen presenting cells, leading to an increase in proinflammatory cytokine production and cytotoxic T cell effector functions. Furthermore, we demonstrate a novel role for Fes in regulating the presentation of IL-12 on macrophage cell surfaces to enhance T-cell activation. Our results highlight Fes as a novel innate immune checkpoint with potential to serve as predictive biomarker to effective immune checkpoint blockade, and a potential novel therapeutic target for improved response to immunotherapy.

Immunology
Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

Duygu Ozmadenci,Jayanth S. Shankara Narayanan,Jacob Andrew,Marjaana Ojalill,Allison M. Barrie,Shulin Jiang,Samhita Iyer,Xiao Lei Chen,Michael Rose,Valeria Estrada,Alfredo Molinolo,Thomas Bertotto,Zbigniew Mikulski,Michael C. McHale,Rebekah R. White,Denise C. Connolly,Jonathan A. Pachter,Vijay K. Kuchroo,Dwayne G. Stupack,David D. Schlaepfer

DOI: https://doi.org/10.1073/pnas.2117065119

IF: 11.1

2022-04-25

Proceedings of the National Academy of Sciences

Abstract:Significance High-grade serous ovarian carcinoma (HGSOC) is an immunotherapy-resistant lethal cancer. An HGSOC hallmark is elevated checkpoint pathway ligand expression that limits antitumor immune responses. Computational, preclinical, and patient tumor multiplexed analyses revealed that tumor-associated focal adhesion kinase (FAK) activation regulates CD155 expression, a checkpoint ligand for TIGIT (T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains). Using an aggressive mouse ovarian tumor model, we find that combined oral FAK inhibitor plus function-blocking TIGIT antibody immunotherapy reduced tumor burden, prolonged mouse survival, and led to immune cell activation and tertiary lymphoid structure formation, hallmarks of an antitumor immune response. As FAK is commonly overexpressed in HGSOC tumors, targeting FAK and TIGIT may limit tumor immune evasion.
Study Progress of Fas/Fas L and Survivin in Breast Cancer

CUI Xiao-mei,GUO Wei-dong,ZHANG Hui-jie

2010-01-01

Abstract:Breast cancer is a kind of hormone(estrogen) depend solid tumor,its occurrence is correlated with apoptosis blocking of the tumor cells.Fas /Fas L play an important role in apoptosis blocking of breast tumor cells.they have clinical value in diagnosis,therapy and prognosis of breast cancer.Survivin is a newly identified member of the the inhibitor of apoptosis protein(IAP) family,which can regulate cell proliferation and apoptosis.In human maliglnant tumor,high expression of urvivin suggests poor prognosis.This article reviewed the relationship of Fas /FasL and Survivin in human breast cancer.
Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

Elisabet Cuyàs,Stefano Pedarra,Sara Verdura,Miguel Angel Pardo,Roderic Espin Garcia,Eila Serrano-Hervás,Àngela Llop-Hernández,Eduard Teixidor,Joaquim Bosch-Barrera,Eugeni López-Bonet,Begoña Martin-Castillo,Ruth Lupu,Miguel Angel Pujana,Josep Sardanyès,Tomás Alarcón,Javier A. Menendez

DOI: https://doi.org/10.1038/s41420-024-02184-z

2024-10-01

Cell Death Discovery

Abstract:Fatty acid synthase (FASN)-catalyzed endogenous lipogenesis is a hallmark of cancer metabolism. However, whether FASN is an intrinsic mechanism of tumor cell defense against T cell immunity remains unexplored. To test this hypothesis, here we combined bioinformatic analysis of the FASN-related immune cell landscape, real-time assessment of cell-based immunotherapy efficacy in CRISPR/Cas9-based FASN gene knockout ( FASN KO ) cell models, and mathematical and mechanistic evaluation of FASN-driven immunoresistance. FASN expression negatively correlates with infiltrating immune cells associated with cancer suppression, cytolytic activity signatures, and HLA-I expression. Cancer cells engineered to carry a loss-of-function mutation in FASN exhibit an enhanced cytolytic response and an accelerated extinction kinetics upon interaction with cytokine-activated T cells. Depletion of FASN results in reduced carrying capacity, accompanied by the suppression of mitochondrial OXPHOS and strong downregulation of electron transport chain complexes. Targeted FASN depletion primes cancer cells for mitochondrial apoptosis as it synergizes with BCL-2/BCL-X L -targeting BH3 mimetics to render cancer cells more susceptible to T-cell-mediated killing. FASN depletion prevents adaptive induction of PD-L1 in response to interferon-gamma and reduces constitutive overexpression of PD-L1 by abolishing PD-L1 post-translational palmitoylation. FASN is a novel tumor cell-intrinsic metabolic checkpoint that restricts T cell immunity and may be exploited to improve the efficacy of T cell-based immunotherapy.

cell biology
Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

Shi-Yong Li,Bo Yu,Ping An,Jia-Chen Wei,Fu-Yi Zuo,Hui-Yun Cai

Abstract:Background: FasL expression was reported to be associated with hepatic metastasis of colorectal cancer. The aim of this study was to study FasL gene expression in colorectal carcinoma and its influences on biological behavior and hepatic metastasis of colorectal carcinoma. Methods: FasL gene expressions were examined with reverse transcriptase-polymerase chain reaction (RT-PCR) in the primary focus of colorectal carcinoma, adjacent cancerous mucosae, and metastasized liver focus from colorectal cancer. HR-8348 cells of human rectal cancer cell line were transfected with FasL cDNA. Cell growth suppression rate and response to 5-FU and carboplatin were observed and analyzed with the MTT method. Results: FasL gene expression was detected in the primary focus of colorectal cancer (n=58), adjacent cancerous mucosae (n=58), and metastasized hepatic tumor tissues (n=28). The positive rate of FasL expression was 24% (14/58), 8% (5/58), and 100% (58/58) in the primary focus, adjacent cancerous mucosae and metastasized hepatic tumor tissues respectively. FasL expression rate in the metastasized hepatic tumor tissues was higher than that in the primary focus (X(2)=43.49, P<0.01) and adjacent cancerous mucosae (X(2)=57.66, P<0.01). In a group of patients with hepatic metastasis, the FasL expression rate in primary focus was higher than that in patients without hepatic metastasis (X(2)=3.96, P<0.05). In vitro study positive expression of FasL was shown in transfected HR-8348 cells. When 5-FU or carboplatin was added, there was a significant difference in growth suppression rate between FasL positive and controlled cancer cells (t=9.02, t=11.93, P<0.01). Under the same concentration of chemotherapeutic agents, the survival rate of FasL positive HR-8348 cells was higher than that of controlled cells. Conclusions: FasL positive cancer cells are powerfully resistant to chemotherapeutic agents. The expression of the FasL gene in colorectal cancer cells is related to immune evasion to escape from being killed by immune cells, showing stronger drug-resistance, and it facilitates hepatic metastasis.
Nuclear FAK aggravates CD8+ T cell exhaustion via the SP1-IL-6 axis in colorectal cancer

Hao Kong,Xiangji Wu,Qingxin Yang,Chunwei Wu,Xin Yu,Jie Yang,Dai Xie,Yu Dai,Lang Chen,Panpan Ma,Siqi Dai,Libin Huang,Chong Chen,Peng Mi,Yong Peng,Hubing Shi,Dunfang Zhang,Nengwen Ke,Bing Hu,Zongguang Zhou,Dan Cao,Ping Wang,Lu Chen,Yun-Hua Liu,Hong Jiang

DOI: https://doi.org/10.1101/2024.07.24.604770

2024-07-24

Abstract:Although immune checkpoint blockade (ICB) therapy has shown promise in colorectal cancer patients with high microsatellite instability (MSI-H), response rates remain low for the majority of patients. Key challenges include the exhaustion of CD8+ T cells and the presence of immunosuppressive cells within the tumor microenvironment. By integrating digital spatial profiling and scRNA sequencing, we found that the tumor-intrinsic activation of focal adhesion kinase (FAK) was strongly correlated with the heterogeneity and exhaustion of CD8+ T cells within the spatial context of the tumor microenvironment and correlated with patient survival. Pharmacological inhibition or genetic loss of FAK enhanced antitumor immune responses and synergistically potentiated αPD-1 and αTIM-3 immunotherapy by augmenting CD8+ T cell cytotoxicity and restoring exhaustion in preclinical models of colorectal cancer. Mechanistically, nuclear FAK was found to regulate SP1/IL-6-mediated T cell exhaustion and the transcription of proinflammatory cytokines/chemokines. These findings underscore FAK's pivotal role in CD8+ T cell exhaustion within the immunosuppressive tumor microenvironment, suggesting that FAK is a promising target for advancing cancer immunotherapy.

Immunology
Apoptosis and Potential Immunoregulation Mediated by Fas Molecular

Xi Lu,Ning-Li Li

DOI: https://doi.org/10.3969/j.issn.1674-7666.2006.04.011

2006-01-01

Abstract:As a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor superfamily, Fas (CD95) plays an important role in apoptosis and immunoregulation. Once Fas binds with its ligand, known as Fas ligand, the cells expressing Fas goes to program cell death or apoptosis. Apoptosis mediated by Fas-FasL involves in the clonal deletion of T cell and B cell in thymus and bone marrow at the early stage of the cell’s differentiation. CTL and NK kill their target cells by Fas and FasL interaction. So the Fas and FasL are very important elements in maintaining immune system homeostasis of the human body and involved in autoimmune disorders, tumor development and acquired immune deficiency syndrome.
Expression of FLIP in Human Colon Carcinomas: A New Mechanism of Immune Evasion

Xing Bao-cai,S. Wimmenauer,EH. Farthmann

DOI: https://doi.org/10.1007/s11670-005-0039-9

2005-01-01

Abstract:Objective: It has been proposed that Fas ligand (FasL) may play an important role in immune escape of tumors and FLIP is an important mediator of Fas/FasL pathway. In this study, the expression of FLIP was determined in human colon carcinoma cell lines and tissue to investigate the new mechanism of immune evasion of human colon carcinomas. Methods: RT-PCR and immunohistochemistry (IHC) were performed to investigate the expression of FLIP in human colon carcinoma cell lines SW480, LS174 and twenty human primary colon carcinoma specimens. Results: It was shown that SW480 cells, LS174 cells and primary colon carcinoma specimen constitutively expressed FLIP at the mRNA and protein level. The expression of FLIP was not found in the epithelial cells of normal colon mucosa. Conclusion: FLIP was expressed in human primary colon carcinoma specimens but not in the normal counterpart. It suggested that the expression of FLIP may occur during the malignant transformation from normal colon epithelial cells to colon carcinoma cells. Tumor cells might obtain the ability to resist the Fas-mediated apoptosis by expressing FLIP. The expression of FLIP might contribute to the formation of colon carcinomas.

Figure S2 from Loss of Fas Expression and Function is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy

Clinical Value of FAT1 Mutations to Indicate the Immune Response in Colorectal Cancer Patients.

Blockade of Fas Signaling in Breast Cancer Cells Suppresses Tumor Growth and Metastasis Via Disruption of Fas Signaling-initiated Cancer-related Inflammation*

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

FOS+ B Cells: Key Mediators of Immunotherapy Resistance in Diverse Cancer Types

Loss of Fas Expression and High Expression of HLA-E Promoting the Immune Escape of Early Colorectal Cancer Cells.

Fas-mediated Pathway and Apoptosis in Normal Cervix, Cervical Intraepithelial Neoplasia and Cervical Squamous Cancer.

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

Suppression of Tumor Cell Immune Counterattack by Blocking FasL Expression in Pancreatic Cancer Cells

FasL Expression in Human Colon Carcinomas

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status

Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In Vivo

Fes-deficient macrophages enhance CD8+ T cell priming and tumour control through increased proinflammatory cytokine production and presentation

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

Study Progress of Fas/Fas L and Survivin in Breast Cancer

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

Nuclear FAK aggravates CD8+ T cell exhaustion via the SP1-IL-6 axis in colorectal cancer

Apoptosis and Potential Immunoregulation Mediated by Fas Molecular

Expression of FLIP in Human Colon Carcinomas: A New Mechanism of Immune Evasion